Modus Therapeutics Holding AB (OSTO:MODTX) Research & Development: kr11.12 Mil (TTM As of Mar. 2026)


OSTO:MODTX Modus Therapeutics Holding AB OSTO:MODTX
30 GF Score
Price kr0.37
! 1 Warning Sign
View Full Analysis

What is Modus Therapeutics Holding AB Research & Development?

Modus Therapeutics Holding AB OSTO:MODTX +1.08% 30 Research & Development is kr11.12 Mil as of Mar. 2026. GuruFocus rates OSTO:MODTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Modus Therapeutics Holding AB's Research & Development for the three months ended in Mar. 2026 was kr1.48 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr11.12 Mil.

Modus Therapeutics Holding AB  (OSTO:MODTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Modus Therapeutics Holding AB Research & Development Related Terms

Modus Therapeutics Holding AB Research & Development Historical Data

* Premium members only.

The historical data trend for Modus Therapeutics Holding AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modus Therapeutics Holding AB Research & Development Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 13.54 10.90 8.48 9.07 10.85

Modus Therapeutics Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 3.67 2.61 3.37 1.48
OSTO:MODTX
30GF Score
Modus Therapeutics Holding AB OSTO:MODTX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modus Therapeutics Holding AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr11.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr11.12 Mil mean?
Modus Therapeutics Holding AB (OSTO:MODTX) has a Research & Development of kr11.12 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Modus Therapeutics Holding AB and its competitors.
Is Modus Therapeutics Holding AB's Research & Development too high?
Modus Therapeutics Holding AB's current Research & Development is kr11.12 Mil. Overall, Modus Therapeutics Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's Research & Development compare to VRTX and REGN?
Modus Therapeutics Holding AB's Research & Development of kr11.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Modus Therapeutics Holding AB and its competitors. Modus Therapeutics Holding AB's current Research & Development is kr11.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current Research & Development of kr11.12 Mil. The current Research & Development is kr11.12 Mil. Modus Therapeutics Holding AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current Research & Development is kr11.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modus Therapeutics Holding AB Business Description

Address Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
30GF Score

Get the complete analysis for OSTO:MODTX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.37
Price